ArticleJournal of diabetes science and technology2026
Practical Approach to Continuous Glucose Monitoring Interpretation and Automated Insulin Delivery Use in Pregnancy: Considerations for Obstetric Providers.
Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.Diabetes care · 2026Trial
- [Management of hyperglycemia in pregnancy (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Automated Insulin Delivery in Pregnancy With Type 1 Diabetes: An Integrative Review of Clinical Evidence, Socio-Technical Implementation and Equity.Journal of diabetes research · 2026Review
- Optimizing Automated Insulin Delivery Systems for Pregnancy.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While automated insulin delivery (AID) systems have multiple well-established benefits outside of pregnancy and are widely used in non-pregnant individuals with type 1 diabetes (T1D), none of the commercially available AID systems in North America are approved for use during pregnancy. Use of commercially available AID systems off-label in pregnancy is currently limited by: (1) glucose targets higher than the fasting glucose target range recommended during pregnancy and (2) algorithms which were not designed for the dynamic changes in insulin resistance which occur across gestation. However, as AID use in the general population expands, many individuals will opt to continue using these systems off-label during pregnancy, and thus, guidance for providers regarding AID use and optimization during pregnancy is of the utmost importance. A cornerstone to the effective use of AID systems is the systematic and accurate interpretation of continuous glucose monitoring (CGM) data. One obstacle to the use of both CGM and AID systems by obstetric providers is the lack of comfort with CGM interpretation. We therefore present here: (1) a systematic approach to CGM interpretation during pregnancy and (2) practical guidance regarding AID use during pregnancy for individuals who opt to use commercially available AID systems off-label during pregnancy after consideration of individualized risks and benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.